Fanny Boursin
Overview
Explore the profile of Fanny Boursin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drouin A, Durand L, Esnault C, Gaboriaud P, Leblond V, Karim S, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40086820
The cell adhesion protein CD56 has been identified as a potential therapeutic target in several solid tumors and hematological malignancies. Recently, we developed a CD56-directed antibody-drug conjugate (ADC), called Adcitmer...
2.
Vozgirdaite D, Allard-Vannier E, Velge-Roussel F, Douez E, Jolivet L, Boursin F, et al.
Nanoscale
. 2025 Jan;
17(7):4058-4072.
PMID: 39775761
Trophoblast cell-surface antigen 2 (TROP 2) has re-emerged as a promising biomarker in triple-negative breast cancer (TNBC), with high overexpression in many TNBC cases. However, despite its potential and approval...
3.
Douez E, Allard-Vannier E, Amar I, Jolivet L, Boursin F, Maisonial-Besset A, et al.
J Control Release
. 2024 Jan;
366:567-584.
PMID: 38215985
Trastuzumab emtansine (Kadcyla®) was the first antibody-drug conjugate (ADC) approved by the Food and Drug Administration in 2013 against a solid tumor, and the first ADC to treat human epidermal...
4.
Blin T, Parent C, Pichon G, Guillon A, Jouan Y, Allouchi H, et al.
Eur J Pharm Biopharm
. 2023 Dec;
195:114163.
PMID: 38086491
Like pneumonia, coronavirus disease 2019 (COVID-19) is characterized by a massive infiltration of innate immune cells (such as polymorphonuclear leukocytes) into the airways and alveolar spaces. These cells release proteases...
5.
Aubrey N, Gouilleux-Gruart V, Dhommee C, Mariot J, Boursin F, Albrecht N, et al.
Antibodies (Basel)
. 2022 Aug;
11(3).
PMID: 35997348
Bispecific antibodies (BsAbs) represent an important advance in innovative therapeutic strategies. Among the countless formats of BsAbs, fusion with molecules such as anticalins linked to a monoclonal antibody (mAb), represents...
6.
Jolivet L, Amar I, Horiot C, Boursin F, Colas C, Letast S, et al.
Pharmaceutics
. 2022 Jul;
14(8).
PMID: 35893780
Antibody-drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment-drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are...
7.
Jiacomini I, Beltramino M, Boursin F, Minozzo J, de Moura J, Billiald P, et al.
Int J Biol Macromol
. 2022 Jul;
216:465-474.
PMID: 35803408
The use of monoclonal antibodies (mAbs) in therapy is gradually advancing and discussions entail its safety, rentability and effectiveness. To this date, around a hundred mAbs have been approved by...
8.
Cnudde T, Lakhrif Z, Bourgoin J, Boursin F, Horiot C, Henriquet C, et al.
Antibodies (Basel)
. 2020 Apr;
9(2).
PMID: 32326443
In order to increase the successful development of recombinant antibodies and fragments, it seems fundamental to enhance their expression and/or biophysical properties, such as the thermal, chemical, and pH stabilities....
9.
Karim-Silva S, Becker-Finco A, Jiacomini I, Boursin F, Leroy A, Noiray M, et al.
Toxins (Basel)
. 2020 Apr;
12(4).
PMID: 32316084
Envenoming due to spider bites still remains a neglected disease of particular medical concern in the Americas. To date, there is no consensus for the treatment of envenomed patients, yet...
10.
Le Roux D, Djokic V, Morisse S, Chauvin C, Dore V, Lagree A, et al.
Vaccine
. 2019 Dec;
38(6):1457-1466.
PMID: 31864855
Toxoplasmosis is a zoonotic disease caused by the parasite Toxoplasma gondii. Up to a third of the global human population is estimated to carry a T. gondii infection, which can...